Yi-Hong Wu

Yi-Hong Wu

Auto-generated profile, based on publicly available information

Yi-Hong Wu

Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2026 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
CLCheng-Chien Lai
Cheng-Chien Lai
SHShao-Sung Huang
Shao-Sung Huang
YLYa-Wen Lu
Ya-Wen Lu
Chung-Kuan WuChung-Kuan Wu
Chung-Kuan Wu
YWYi-Hong Wu
Yi-Hong Wu
WTWei-Cheng Tseng
Wei-Cheng Tseng

7 July 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
CLCheng-Chien Lai
Cheng-Chien Lai
SHShao‐Sung Huang
Shao‐Sung Huang
YLYa‐Wen Lu
Ya‐Wen Lu
Chung-Kuan WuChung-Kuan Wu
Chung-Kuan Wu
YWYi‐Hong Wu
Yi‐Hong Wu
WTWei-Cheng Tseng
Wei-Cheng Tseng
Background: Improvement in left ventricular ejection fraction (LVEF) aligns with better outcomes in patients with heart failure with reduced EF. Nonetheless, detailed relationship between the extent of LVEF improvement and the risks of adverse cardiorenal events remains unclear. Methods: From 2011 to 2021, a retrospective cohort of 601 patients with heart failure with reduced EF who underwent follow‐up echocardiography within 6 months was enrolled and followed until March 31, 2022. Patients were classified as nonimprovement (follow‐up LVEF ≤40% or 40% with 10% to 40% and ≥20% improvement). Multivariable Cox regression was used to estimate associations between LVEF improvement and the composite and individual risks of all‐cause mortality, major adverse cardiovascular events, and major adverse kidney events. Results: Over a median follow‐up of 2.62 years, 67 deaths, 121 major adverse cardiovascular events, and 100 major adverse kidney events occurred. Compared with the nonimprovement group, only the full‐improvement group was independently associated with lower risks of the composite outcome (adjusted hazard ratio [aHR], 0.36 [95% CI, 0.20–0.63]), major adverse cardiovascular events (aHR, 0.33 [95% CI, 0.18–0.61]), and major adverse kidney events (aHR, 0.39 [95% CI, 0.19–0.82]). Graded associations between LVEF improvement and decreased cardiorenal risks were confirmed in spline analyses and consistent across subgroup and sensitivity analyses. Maintenance of improved LVEF for 1 year was further associated with lower risks for the adverse cardiorenal outcomes. Conclusions: Greater and sustained LVEF improvement is linked to lower risks of cardiorenal events in heart failure with reduced EF, emphasizing the value of incorporating improvement magnitude into risk assessment.